Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 75

1.

Inquiries about and initiation of buprenorphine treatment in an inner-city clinic.

Cunningham CO, Giovanniello A, Sacajiu G, Li X, Brisbane M, Sohler NL.

Subst Abus. 2009 Jul-Sep;30(3):261-2. doi: 10.1080/08897070903041301.

2.

Office-Based Opioid Treatment with Buprenorphine (OBOT-B): Statewide Implementation of the Massachusetts Collaborative Care Model in Community Health Centers.

LaBelle CT, Han SC, Bergeron A, Samet JH.

J Subst Abuse Treat. 2016 Jan;60:6-13. doi: 10.1016/j.jsat.2015.06.010. Epub 2015 Jun 26.

3.

Buprenorphine treatment in an urban community health center: what to expect.

Cunningham C, Giovanniello A, Sacajiu G, Whitley S, Mund P, Beil R, Sohler N.

Fam Med. 2008 Jul-Aug;40(7):500-6.

4.

Psychiatric Comorbidity and Substance Use Outcomes in an Office-Based Buprenorphine Program Six Months Following Hurricane Sandy.

Tofighi B, Grossman E, Goldfeld KS, Williams AR, Rotrosen J, Lee JD.

Subst Use Misuse. 2015;50(12):1571-8. doi: 10.3109/10826084.2015.1023455. Epub 2015 Nov 19.

PMID:
26623697
5.

Persistence and healthcare utilization associated with the use of buprenorphine/naloxone film and tablet formulation therapy in adults with opioid dependence.

Clay E, Khemiri A, Zah V, Aballéa S, Ruby J, Asche CV.

J Med Econ. 2014 Sep;17(9):626-36. doi: 10.3111/13696998.2014.925463. Epub 2014 Jun 6.

PMID:
24841329
6.

Unobserved versus observed office buprenorphine/naloxone induction: a pilot randomized clinical trial.

Gunderson EW, Wang XQ, Fiellin DA, Bryan B, Levin FR.

Addict Behav. 2010 May;35(5):537-40. doi: 10.1016/j.addbeh.2010.01.001. Epub 2010 Jan 18.

7.

Treating opioid addiction with buprenorphine-naloxone in community-based primary care settings.

Mintzer IL, Eisenberg M, Terra M, MacVane C, Himmelstein DU, Woolhandler S.

Ann Fam Med. 2007 Mar-Apr;5(2):146-50.

8.

Initiating buprenorphine treatment for hospitalized patients with opioid dependence: A case series.

Suzuki J, DeVido J, Kalra I, Mittal L, Shah S, Zinser J, Weiss RD.

Am J Addict. 2015 Jan;24(1):10-4. doi: 10.1111/ajad.12161.

PMID:
25823630
9.

Buprenorphine-naloxone maintenance following release from jail.

Lee JD, Grossman E, Truncali A, Rotrosen J, Rosenblum A, Magura S, Gourevitch MN.

Subst Abus. 2012;33(1):40-7. doi: 10.1080/08897077.2011.620475.

10.

Determinants of buprenorphine treatment for opioid dependence.

Murphy SM, Fishman PA, McPherson S, Dyck DG, Roll JR.

J Subst Abuse Treat. 2014 Mar;46(3):315-9. doi: 10.1016/j.jsat.2013.09.003. Epub 2013 Oct 25.

PMID:
24209382
11.

Clinic-based treatment of opioid-dependent HIV-infected patients versus referral to an opioid treatment program: A randomized trial.

Lucas GM, Chaudhry A, Hsu J, Woodson T, Lau B, Olsen Y, Keruly JC, Fiellin DA, Finkelstein R, Barditch-Crovo P, Cook K, Moore RD.

Ann Intern Med. 2010 Jun 1;152(11):704-11. doi: 10.7326/0003-4819-152-11-201006010-00003.

12.

Predictors of outcome after short-term stabilization with buprenorphine.

Hillhouse M, Canamar CP, Ling W.

J Subst Abuse Treat. 2013 Mar;44(3):336-42. doi: 10.1016/j.jsat.2012.08.016. Epub 2012 Sep 26.

13.

From methadone to buprenorphine: changes during a 10 year period within a national opioid maintenance treatment programme.

Riksheim M, Gossop M, Clausen T.

J Subst Abuse Treat. 2014 Mar;46(3):291-4. doi: 10.1016/j.jsat.2013.10.006. Epub 2013 Oct 14.

PMID:
24210532
14.

A novel community-based buprenorphine program: client description and initial outcomes.

Daniels AM, Salisbury-Afshar E, Hoffberg A, Agus D, Fingerhood MI.

J Addict Med. 2014 Jan-Feb;8(1):40-6. doi: 10.1097/ADM.0000000000000004.

PMID:
24394496
15.

Opioid agonist treatment for pharmaceutical opioid dependent people.

Nielsen S, Larance B, Degenhardt L, Gowing L, Kehler C, Lintzeris N.

Cochrane Database Syst Rev. 2016 May 9;(5):CD011117. doi: 10.1002/14651858.CD011117.pub2. Review.

PMID:
27157143
16.
18.

A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia.

Burns L, Gisev N, Larney S, Dobbins T, Gibson A, Kimber J, Larance B, Mattick RP, Butler T, Degenhardt L.

Addiction. 2015 Apr;110(4):646-55. doi: 10.1111/add.12834.

PMID:
25516077
19.

Predictive factors for relapse in patients on buprenorphine maintenance.

Ferri M, Finlayson AJ, Wang L, Martin PR.

Am J Addict. 2014 Jan-Feb;23(1):62-7. doi: 10.1111/j.1521-0391.2013.12074.x. Epub 2013 Jun 10.

20.

Psychiatric comorbidity, red flag behaviors, and associated outcomes among office-based buprenorphine patients following Hurricane Sandy.

Williams AR, Tofighi B, Rotrosen J, Lee JD, Grossman E.

J Urban Health. 2014 Apr;91(2):366-75. doi: 10.1007/s11524-014-9866-7.

Supplemental Content

Support Center